FANCD2OS: A Potential Drug Target Or Biomarker (G115795)

Target Name: FANCD2OS

NCBI ID: G115795

FANCD2OS

FANCD2OS: A Potential Drug Target Or Biomarker

FanCD2OS, also known as FANCD2OS variant 1, is a protein that is expressed in many tissues of the body, including the lungs, heart, kidneys, and intestines. It is a member of the CD28 superfamily and is involved in the regulation of cell adhesion, migration, and invasion.

FANCD2OS has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions in these diseases have been studied extensively, and its potential as a drug target has led to a number of research studies and clinical trials.

One of the key reasons for the interest in FANCD2OS is its ability to interact with several different cell surface molecules, including adhesion molecules such as cadherin and E-cadherin, as well as cell surface antigens such as CD33 and CD133. This makes it a promising target for drugs that can modulate cell adhesion and migration, such as those used in cancer treatment.

In addition to its role in cell adhesion and migration, FANCD2OS is also involved in the regulation of cell survival and proliferation. Its expression has been shown to be associated with the survival and proliferation of cancer cells, and it has been proposed as a potential biomarker for cancer diagnosis and treatment.

FANCD2OS has also been shown to be involved in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Its expression has been observed in the brains of individuals with these conditions, and it has been suggested as a potential therapeutic target for these diseases.

In addition to its potential role in neurodegenerative diseases, FANCD2OS has also been shown to be involved in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Its expression has been observed in the tissues of individuals with these conditions, and it has been suggested as a potential therapeutic target for these disorders.

Despite its potential as a drug target or biomarker, FANCD2OS has not yet been fully characterized, and more research is needed to fully understand its functions in these diseases. Additionally, the development of FANCD2OS-based therapies may also require the development of new techniques for its production and delivery, as well as the testing of potential efficacy and safety in clinical trials.

In conclusion, FANCD2OS is a protein that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions in these diseases have been studied extensively, and its potential as a drug target has led to a number of research studies and clinical trials. Further research is needed to fully understand its functions in these diseases and the development of FANCD2OS-based therapies.

Protein Name: FANCD2 Opposite Strand

The "FANCD2OS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FANCD2OS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets